# US 2014/0154704 A1 · Monoclonal Antibodies with Specficity for Fetal Erythroid Cells

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2014/0154704 A1
- Document ID: US20140154704A1
- Status: Published application
- Kind: A1
- Application number: 14/028,027
- Filed: 2013-09-16
- Published: 2014-06-05
- Earliest claimed: 2004-03-31
- Assignees: AdnaGen AG
- Applicants: Adnagen AG
- Inventors: Christiane Hollmann; Silke Zimmermann; Stefan Stachelhaus; Winfried Albert
- Web page: https://patentgrep.com/patent/US20140154704A1

## CPC

- G01N 33/56966: {Animal cells}
- C07K 16/28: against receptors, cell surface antigens or cell surface determinants
- G01N 33/5094: {for blood cell populations (red blood cells G01N33/80)}
- G01N 33/577: involving monoclonal antibodies {binding reaction mechanisms characterised by the use of monoclonal antibodies (G01N33/5302 - G01N33/576 take precedence)}
- G01N 33/80: involving blood groups or blood types {or red blood cells (white blood cells G01N33/56972)}
- C07K 2317/14: Specific host cells or culture conditions, e.g. components, pH or temperature
- G01N 2333/70582: CD71
- G01N 2469/10: Detection of antigens from microorganism in sample from host
- Y10T 436/25125: Digestion or removing interfering materials
- Y10T 436/25375: Liberation or purification of sample or separation of material from a sample [e.g., filtering, centrifuging, etc.]
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- Y10T: TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION

## Abstract

The present invention concerns a monoclonal antibody and corresponding hybridoma cells and antigens suitable for isolating fetal cells from maternal blood. The inventive monoclonal antibody reacts with a surface antigen present on fetal red blood cells including their nucleated precursor cells, but not with surface antigens on adult erythroid cell.

## Claims

### Claim at position 1

-16. (canceled)

### Claim 17

A method for detection or identification of fetal red blood cells in a sample comprising
labelling said fetal red blood cells and their nucleated precursor cells with an antibody; and
reacting the antibody with a surface antigen present on said fetal red blood cells and their nucleated precursor cells, but not with one or more surface antigens on adult erythroid cells.

### Claim 18 (depends on 18)

The method according to claim 18, wherein the sample is maternal blood.

### Claim 19 (depends on 18)

The method according to claim 18, further comprising analyzing said fetal red blood cells and their nucleated precursor cells, subsequent to the detection and identification, for a chromosomal or genetic defects.

### Claim 20 (depends on 18)

The method according to claim 18, further comprising separating fetal red blood cells and their nucleated precursor cells binding the antibody by flow cytometry, solid phase separation, immunomagnetic bead separation, or panning on plastic surfaces.

### Claim 21 (depends on 18)

The method according to claim 18, wherein the antibody has reactivity with fetal erythroid cells and their nucleated precursor cells which express the CD71 antigen but are negative for CD45 antigen expression.

### Claim 22 (depends on 18)

The method according to claim 18, wherein the antibody does not react with CD71 antigen.